Daratumumab

DARZALEX®

Overview

Darzalex® is not chemotherapy. Darzalex® is a monoclonal antibody that works in several ways. One way this monoclonal antibody works is by attaching itself to multiple myeloma cells in your body and directly killing them, and/or allowing your immune system to destroy them.

Darzalex® targets and attaches to a protein called CD38, which is present on the surface of certain types of cells (eg, red blood cells) and is also present in high numbers on multiple myeloma cells. Since Darzalex® targets the CD38 protein, it may also affect other cells with this protein on their surface.

SparkCures ID 51
Developed By Janssen Research & Development
Brand Name Darzalex®
Generic Name Daratumumab
Additional Names CD38 mAb, HuMax-CD38
Treatment Classifications
Treatment Targets
Tags
  • FDA Approved
  • Published Results

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).

Resources